ASPEN PHARMACARE HOLDINGS LIMITED - Notification in terms of S122(3) of the Companies Act and S3.83(b) of the JSE Listings Requirements

Notification in terms of S122(3) of the Companies Act and S3.83(b) of the JSE Listings Requirements

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen Holdings" or "the Company")



NOTIFICATION IN TERMS OF SECTION 122(3) OF THE COMPANIES ACT AND SECTION 3.83(b) OF THE JSE LISTINGS
REQUIREMENTS



In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (“the Act”), and section
3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised
that:

Glaxo Group Limited (“GSK”), has disposed of Aspen Holdings ordinary shares, such that its
beneficial interests in Aspen Holdings now amounts to 12.4% of the total number of shares in
issue.

Aspen Holdings hereby confirms that it has received the required notice from GSK in terms of
section 122(1)(a) of the Act. As required in terms of section 122(3)(a) of the Act, Aspen Holdings
will file the required notice with the Takeover Regulation Panel.


Durban
20 November 2013

Sponsor
Investec Bank Limited

Date: 20/11/2013 05:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.